Scotia calls in administrators:
This article was originally published in Clinica
The Scotia group of companies, UK developers of Foscan, a photodynamic therapy for head and neck cancers, has gone into administration. The administrator, accountancy firm Ernst & Young, is not writing off Scotia completely, however. Joint administrator Andrew Wollaston said: "Scotia has developed an impressive intellectual property portfolio with both current and future value opportunities and our immediate strategy is to explore all options in order to preserve and enhance the company's key platform technologies, including Foscan."